Skip to main content
main-content

HFpEF and diabetes

Diagnosis and management in the wake of EMPEROR-Preserved
Webinar

Watch on-demand

Join cardiologist Lars Rydén, endocrinologist Alice Cheng, and primary care practitioner Kevin Saunders who discuss the diagnosis and management of people with type 2 diabetes and shortness of breath in primary care, and how the positive findings of EMPEROR-Preserved will now shape the care of these patients. Watch now

Keep up with the latest news on HFpEF

03-01-2022 | Empagliflozin | News

Empagliflozin indication extended to all heart failure in USA

Click through to read more on this announcement

02-28-2022 | Canagliflozin | News

Virtual CHIEF-HF trial supports canagliflozin in heart failure

The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.

02-28-2022 | Empagliflozin | News

EMPULSE shows empagliflozin benefit in acute heart failure

Starting empagliflozin as soon as feasible after hospital admission for acute heart failure reduces symptom burden and the risk for repeat episodes and mortality over the following 3 months, report the EMPULSE investigators.

08-27-2021 | ESC 2021 | Conference coverage | News

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Interviews on heart failure

Mikhail Kosiborod

11-01-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

Kevin Fernando

08-29-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: The implications for primary care

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

Stefan Anker

08-29-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.

Adriaan Voors

03-02-2022 | Empagliflozin | Video

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox